Cognite Recognized as a Leader in Industrial Data Management Solutions
16.1.2025 15:59:00 CET | Business Wire | Press release
Independent Research Firm positions Cognite Data Fusion® as a market-leading DataOps and AI platform for enterprise-scale, complex industrial data management projects
Cognite, the global leader in AI for industry, today announced it has been named a Leader in the Verdantix Green Quadrant: Industrial Data Management Solutions 2025 report for providing a market-leading DataOps and AI platform for enterprise-scale, complex Industrial Data Management (IDM) projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114915194/en/
Verdantix Green Quadrant: Industrial Data Management Solutions 2025 (Graphic: Business Wire)
The report recognizes Cognite's platform, Cognite Data Fusion®, for its deeply configurable unstructured and structured industrial data orchestration, fast-paced product development, and world-class offering for complex asset-heavy industrial data and AI projects.
Cognite received a perfect score for its ‘data modeling’ capabilities, the foundational element of Cognite Data Fusion® that enables Cognite customers to adapt to emerging trends and stay ahead in a rapidly evolving technological climate. Additionally, Cognite received perfect scores across 'indirect industrial data acquisition,' 'platform development environment,' and 'platform APIs,' and the highest score for 'unstructured data utilization’ of all data platforms reviewed.
Verdantix also highlighted Cognite Atlas AI™ as an example of innovation in making industrial AI work for practical applications. With its focus on real-world usability, Cognite Atlas AI™ was called out for its ability to streamline agent-driven data retrieval and interpretation, supported by an industrial benchmarking report that helps organizations select the most suitable LLMs for their specific use cases.
“Industrial data management solutions play a critical role in enabling organizations to effectively integrate and leverage their data, particularly as AI becomes increasingly central to industrial operations,” said Joe Lamming, Senior Analyst, Industrial Transformation at Verdantix. “Cognite’s market-leading data modeling capabilities contextualize diverse data types, from structured time series to unstructured documents. We see such capabilities as vital for bridging the gap between raw data and actionable insights and automation. Solutions like those offered by Cognite show how industrial knowledge graphs can ground AI applications in domain-specific, cross-referenced truth, enabling organizations to build useful information systems in complex OT, IT, and ET environments.”
"Data modeling is the cornerstone of Cognite's approach to tackling complex industrial challenges," said Geir Engdahl, Chief Product Officer at Cognite. "Our advanced techniques, including our industrial agent workbench Cognite Atlas AI™, bridge the gap between raw data and actionable insights, making information accessible and meaningful to both humans and AI systems. As generative AI reshapes the industrial landscape, our commitment to robust and flexible data modeling ensures we empower customers with the right foundation for innovative AI-powered solutions tailored to their operational realities."
Cognite Data Fusion® serves as the cornerstone of Cosmo Energy's Digitalization (DX) aspirations," said Noriko Rzonca, Ph.D., Chief Digital Officer Cosmo Energy Holdings. “Generative AI-driven data modeling with Cognite empowers our operations to be safer and more optimized. We are thrilled to see them receive this well-deserved recognition as a leader in Industrial Management Solutions."
Read the full report here: Cognite recognized as a leader in Industrial Data Management solutions
Request a demo of Cognite Data Fusion® and Cognite Atlas AI™ here: cognite.com/request-demo
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
About Verdantix
Verdantix is the essential thought-leader for world-enhancing innovation. We support change-makers with our proprietary data, unique expertise and executive networks. Our impactful analysis is delivered via a digital platform, consulting engagements and in-person events to thousands of decision-makers in more than 100 countries. From offices in London, New York and Boston, the Verdantix research team applies the principles of rigour, accuracy and curiosity to help our globally distributed clients solve their most complex challenges. verdantix.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114915194/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom